AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Photocure ASA

Report Publication Announcement • Jan 8, 2018

3714_rns_2018-01-08_2d96051f-f400-4f91-8f86-aae9138789f1.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Photocure to present at investor meetings in San Francisco

Oslo, Norway, January 8, 2018 - Photocure ASA (OSE: PHO) management is this week conducting investor meetings in San Francisco (US) in connection with the J.P. Morgan healthcare conference. Please find the presentation attached.

Company contact:

Erik Dahl, Chief Financial Officer

Tel: +47 450 55 000

Email: [email protected]

About Photocure

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company focusing on urology. Based on its unique proprietary Photocure Technology® platform, Photocure is committed to developing and commercializing highly selective and minimally invasive solutions to improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). More information about Photocure is available at www.photocure.com, www.hexvix.com, www.cysview.com.